2. Leverage E-detailing as a Sales Force Supplement

Manhattan Research, LLCWhile the market for electronic detailing in the U.S. has reached nearly a point of saturation at roughly half of all practicing physicians, the European market is still in an early stage of development and adoption. In fact, only 15% of European physicians have participated in an electronic detailing program today, a number that has remained statistically stagnant year over year.

However, lack of interest is not a factor on the part of European physicians - who in many cases are not even familiar with electronic detailing as a concept - but rather, a limited supply of programs being offered to physicians in Europe. In fact, almost half of European physicians are not even familiar with electronic detailing as a concept today. That said, the electronic detailing market in Europe does have a few companies acting as active players - with Pfizer and GlaxoSmithKline (GSK) driving the majority of market share today.

This limited awareness and supply of electronic detailing programs in Europe demonstrate a unique market opportunity which exists in Europe today. Whereas many physicians in the U.S. have been inundated with electronic detailing invitations over the past few years, the market is relatively untapped in Europe currently, allowing savvy, ahead-of-the-curve companies to capitalise on physician interest at a time when electronic detailing is still somewhat of a novelty.

One of the major drivers, which has encouraged companies such as Pfizer and GSK to take advantage of electronic promotional opportunities, is the positive effect e-detailing tends to have on the physician's overall time spent with a sales representative from a given company. Although the sales force initially looked at e-detailing with skepticism, wondering if online promotion would render the traditional sales call obsolete, most reps are actually seeing the opposite effect - that the e-detail actually increases the overall time spent with the rep. The office visit takes on a new life in the context of a growing array of clinical information sources - online and offline. Results from the recent Manhattan Research study Taking the Pulse® Europe corroborate these findings, showing that physicians participating in edetailing are more likely to report they spend more time with a rep as a result of an edetail, as opposed to taking away time from the rep as a result. Savvy, ahead-of-the-curve companies across Europe are capitalising on e-detailing as a low-cost opportunity to increase physician engagement and improve the overall sales call quality.

Five Emerging Trends about European Consumer and Physician Use of New Media

1. Connecting to Physicians, on Their Terms

2. Leverage E-detailing as a Sales Force Supplement

3. Online Physician Portals Evolve into Clinical Resources, Beyond News

4. Empowered European Consumers Speak with Their Physician about Information Found Online

5. In the Absence of Direct-to-Consumer Advertising, Online Content Is Critical

For further information, visit:
http://www.manhattanresearch.com/2008EUTrends.aspx

Source: white paper derived from Cybercitizen® Health Europe and Taking the Pulse® Europe
© Manhattan Research, LLC, 2007

Most Popular Now

Roche's COVID-19 antibody test receives FDA Emerge…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) (1) for its new Elecsys® Ant...

Pfizer and BioNTech dose first participants in the…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 va...

Johnson & Johnson announces collaboration to e…

Johnson & Johnson (the Company) (NYSE: JNJ) announced a collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Emergent BioSolutions, Inc. to...

Early indicators of vaccine efficacy

Ludwig-Maximilians-Universität (LMU) in Munich researchers have shown that a specific class of immune cells in the blood induced by vaccination is an earlier indicator of...

Arthritis drug may improve respiratory function in…

A small study in Greece found that the clinically approved anti-inflammatory drug anakinra, used to treat rheumatoid arthritis, improved respiratory function in patients ...

Researchers urge clinical trial of blood pressure …

Researchers in the Ludwig Center at the Johns Hopkins Kimmel Cancer Center report they have identified a drug treatment that could - if given early enough - potentially r...

Frankfurt researchers discover potential targets f…

A team of biochemists and virologists at Goethe University and the Frankfurt University Hospital were able to observe how human cells change upon infection with SARS-CoV-...

Official COVID-19 deaths underestimate the full im…

According to a study by Charité - Universitätsmedizin Berlin, the northern Italian city of Nembro recorded more deaths during March 2020 than between January and December...

Local climate unlikely to drive the early COVID-19…

Local variations in climate are not likely to dominate the first wave of the COVID-19 pandemic, according to a Princeton University study published May 18 in the journal ...

Antibody neutralizes SARS and COVID-19 coronavirus…

An antibody first identified in a blood sample from a patient who recovered from Severe Acute Respiratory Syndrome in 2003 inhibits related coronaviruses, including the c...

Vitamin D linked to low virus death rate

A new study has found an association between low average levels of vitamin D and high numbers of COVID-19 cases and mortality rates across 20 European countries. The r...

AstraZeneca advances response to global COVID-19 c…

AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations...